Amneal Pharmaceuticals (AMRX) Tops Q4 EPS by 5c, FY EPS Guidance Misses

Amneal Pharmaceuticals (NYSE: AMRX) reported Q4 EPS of $0.33, $0.05 better than the analyst estimate of $0.28. Revenue for the quarter came in at $498 million versus the consensus estimate of $484.3 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2019 EPS of $0.94-$1.04, versus the consensus of $1.24.

• Adjusted EBITDA $600 million - $650 million

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity